Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 13 of 23, showing 5 Applications out of 112 total, starting on record 61, ending on 65

# Protocol No Study Title Investigator(s) & Site(s)

61.

ECCT/24/10/05   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

62.

ECCT/24/10/04   Cabotegravir + Rilpivirine Inj
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Long-acting Combination Therapy Studies   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project Clinical Research Centre (Kericho county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Aga Khan University Hospital Nairobi (Nairobi City county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

63.

ECCT/24/07/02   TMC278LAHTX4002
    A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Virus Type 1 (HIV-1) Infection Who Participated in Longacting Combination Therapy Studies   
Principal Investigator(s)
1. Reena Shah
Site(s) in Kenya
1. Aga Khan University Hospital Nairobi (Nairobi City county)
2. School of Medicine, College of Health Sciences, Moi University (Uasin Gishu county)
3. Kenya Medical Research Institute-Walter Reed Program (KEMRI-WRP) Clinical Research Site, Kericho, Kenya (Kericho county)
4. University of Nairobi - Kenyatta National Referral Hospital (Nairobi City county)
5. University of Nairobi - Jaramogi Oginga Odinga Teaching and Referral Hospital (Nairobi City county)
 
View

64.

ECCT/17/08/01   A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults
    A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines.   
Principal Investigator(s)
1. Philip Bejon
Site(s) in Kenya
KEMRI Kilifi
 
View

65.

ECCT/24/11/03   REALISE STUDY PROTOCOL
    A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and 1 Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs 2 Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in 3 School-Aged Children   
Principal Investigator(s)
1. Alejandro Javier Krolewiecki
Site(s) in Kenya
Kwale county
 
View